Sirtex Medical and Magle Group Join Forces to Unleash the Power of EmboCept® S DSM 50 μm

Sirtex Medical and Magle Group Join Forces to Combat Liver and Lung Cancer Globally

WOBURN, Mass., Sept. 8, 2023 /PRNewswire/ — In a landmark collaboration, Sirtex Medical, a trailblazing force in interventional treatment solutions, has teamed up with Magle Group, a Swedish powerhouse in contract development and manufacturing, along with Degradable Starch Microspheres (DSM) sales and marketing. Together, they’re set to revolutionize the global battle against liver and lung cancer.

Under this visionary agreement, Sirtex takes the helm as the exclusive worldwide distributor for Magle Group’s game-changing chemoembolization marvel, EmboCept® S DSM 50 μm. This partnership aims to expand patient access to this groundbreaking product across existing and emerging geographic regions. But that’s not all – Sirtex and Magle are forging a joint development roadmap, poised to amplify their product lineup in the dynamic field of embolization, leveraging Magle Group’s cutting-edge DSM platform.

EmboCept® S DSM 50 μm is a medical marvel, specifically designed for the chemoembolization of liver and lung tumors. It serves as a vital ally in the intra-arterial treatment of inoperable liver and lung tumors, working hand-in-hand with cytostatic agents. What sets it apart is its remarkable degradability, allowing for superselective treatments of individual liver segments and precise targeting of a single liver lobe to combat multifocal, diffuse tumors, and even non-visible micro-tumors.

Justin Pierce, the visionary CEO of Magle Group, exclaims, “Our partnership with Sirtex is poised to unlock the boundless commercial potential of EmboCept® S, our proprietary weapon in the fight against inoperable liver and lung tumors. With Sirtex’s formidable sales force and unwavering commitment to expanding Magle Group’s DSM-based product range in embolization, we’re on the brink of groundbreaking progress.”

The statistics speak for themselves – liver cancer ranks as the fourth leading cause of death worldwide, claiming over 800,000 lives annually, as per the National Institute of Health. Lung cancer, on the other hand, emerges as the deadliest of all, responsible for a staggering 1.8 million annual fatalities out of 2.2 million diagnoses, according to the World Health Organization’s 2020 report.

Kevin R. Smith, the dynamic Chief Executive Officer of Sirtex, adds, “We are on the brink of an exciting new chapter as we diversify our product portfolio to meet the unmet demands in liver and lung oncology. Our partnership with Magle is a testament to our unwavering commitment to enhancing the lives of patients worldwide.”

EmboCept® S DSM 50 µm has already earned its stripes with approvals for sale in Europe, Argentina, Singapore, and Malaysia, marking a significant stride in the global battle against these relentless cancers.

About Sirtex

With a global presence spanning the U.S., Australia, Europe, and Asia, Sirtex is a beacon of hope in the fight against cancer. Their flagship product, SIR-Spheres® Y-90 resin microspheres, represents a groundbreaking targeted radiation therapy designed to revolutionize the battle against liver cancer. Sirtex is dedicated to enhancing the lives of cancer patients around the world, illuminating a brighter future for all.

Leave a Comment